Increased restenosis rates 12 months after coronary implantation of the sirolimus-eluting YUKON-Choice stent compared to the paclitaxel-eluting TAXUS stent

12Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.

Abstract

Background: Previously the polymer-free sirolimus-eluting YUKON-Choice stent (A) has demonstrated noninferiority compared to the polymer-based paclitaxel-eluting TAXUS stent (B). To test for long-term equivalency in unselected real-world coronary lesions of various complexities, we retrospectively compared both stents. Methods: A total of 410 patients with symptomatic coronary artery disease (CAD) were treated with stent A (n = 205) or stent B (n = 205). Baseline clinical characteristics, lesion location, and length and the number of stents implanted per lesion were equally distributed. Clinical follow-up with assessment of major adverse cardiac events (MACE) and noncardiac deaths was obtained at 9 and 12 months. Results: Nominal stent diameter and nominal length of the stented segment were without differences between the groups. The incidence of MACE after 12 months was significantly higher in group A (35.1%) compared to group B (16.6%, P = .001). This was mainly due to increased rates of target-lesion revascularizations in group A (13.7%) vs group B (4.4%, P = .005). No significant differences in target-vessel revascularizations and non-target-vessel revascularizations were observed. In group B, 1 stent thrombosis wasdocumented(0.5%) vsnoneingroup A(P > .05); in each group 1myocardial infarction (MI), but no cardiac deaths occurred; 3 noncardiac deaths in group A (1.5%) vs 7 in group B (3.4%) were observed (P = .3). Conclusions: In contrast to our previous findings indicating no differences in MACE between patients treatedwith the polymer-free sirolimus-eluting YUKON-Choice stent and the polymer-based paclitaxel-eluting TAXUS stent at 6 months, we herewith show that 12 months after percutaneous coronary intervention (PCI) of real-world coronary lesions the YUKON stent appears to be inferior due to increased target-lesion revascularization (TLR) rates as a consequence of delayed restenosis. © 2010 Wiley Periodicals, Inc.

Cite

CITATION STYLE

APA

Ruef, J., Störger, H., Schwarz, F., & Haase, J. (2010). Increased restenosis rates 12 months after coronary implantation of the sirolimus-eluting YUKON-Choice stent compared to the paclitaxel-eluting TAXUS stent. Clinical Cardiology, 33(4). https://doi.org/10.1002/clc.20483

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free